Hikma Pharmaceuticals Plc Stock Today
| HKMPF Stock | USD 24.47 1.91 8.47% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Hikma Pharmaceuticals is trading at 24.47 as of the 28th of November 2024. This is a 8.47 percent increase since the beginning of the trading day. The stock's lowest day price was 24.47. Hikma Pharmaceuticals has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Hikma Pharmaceuticals PLC are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of December 2022 and ending today, the 28th of November 2024. Click here to learn more.
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company was founded in 1978 and is based in London, the United Kingdom. Hikma Pharmaceutical operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. The company has 220.26 M outstanding shares. More on Hikma Pharmaceuticals PLC
Moving together with Hikma Pink Sheet
| 0.87 | MKKGY | Merck KGaA ADR | PairCorr |
| 0.84 | MKGAF | MERCK Kommanditgesells | PairCorr |
| 0.76 | HLN | Haleon plc | PairCorr |
| 0.84 | TAK | Takeda Pharmaceutical | PairCorr |
Moving against Hikma Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Hikma Pink Sheet Highlights
| Chairman | Mazen Darwazah |
| Business Concentration | Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) |
Hikma Pharmaceuticals PLC [HKMPF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC). The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.6 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Hikma Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Hikma Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Hikma Pharmaceuticals PLC classifies itself under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 220.26 M outstanding shares.
Hikma Pharmaceuticals PLC has accumulated about 393 M in cash with 638 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.78.
Check Hikma Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationHikma Pharmaceuticals PLC has a total of 220.26 Million outstanding shares. Hikma Pharmaceuticals secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Hikma Ownership Details
Hikma Pharmaceuticals PLC Risk Profiles
| Mean Deviation | 0.4051 | |||
| Standard Deviation | 1.42 | |||
| Variance | 2.01 | |||
| Risk Adjusted Performance | (0.03) |
Hikma Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Hikma Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Pattern Recognition Now
Pattern RecognitionUse different Pattern Recognition models to time the market across multiple global exchanges |
| All Next | Launch Module |
Hikma Pharmaceuticals Corporate Management
| Engineer Darwazah | Ex CEO | Profile | |
| Khalid Nabilsi | Chief Officer | Profile | |
| CPA CFA | Exec MA | Profile | |
| Brian Hoffmann | Pres Generics | Profile | |
| Hussein Arkhagha | General Counsel | Profile |
Other Information on Investing in Hikma Pink Sheet
Hikma Pharmaceuticals financial ratios help investors to determine whether Hikma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Hikma with respect to the benefits of owning Hikma Pharmaceuticals security.